Acorn Capital Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

Acorn Capital Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-234,039	Closed	-$967K	–	23
2026 Q1	$967K	Sell	234,039 -39,310	-14%	-$147K	0.27%	20
2025 Q4	$1.09M	Hold	273,349	–	–	0.37%	19
2025 Q3	$935K	Buy	273,349 +119,619	+78%	+$308K	0.47%	18
2025 Q2	$292K	Sell	153,730 -89,958	-37%	-$368K	0.19%	21
2025 Q1	$1.75M	Hold	243,688	–	–	1.17%	16
2024 Q4	$5.36M	Buy	+243,688	New	+$3.88M	2.89%	13

Other funds holding XFOR

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acorn Capital Advisors's XFOR Position: Q2 2026 in Review

Acorn Capital Advisors sold out of X4 Pharmaceuticals (XFOR) in Q2 2026, closing a stake of 234,039 shares — an estimated $967K sold.

Acorn Capital Advisors first reported a position in XFOR in Q4 2024 and held it in 6 quarters. The position peaked at $5.36M in Q4 2024. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

Acorn Capital Advisors reported no remaining X4 Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Acorn Capital Advisors sold 234,039 X4 Pharmaceuticals shares in Q2 2026, an estimated $967K.
Acorn Capital Advisors first reported a position in X4 Pharmaceuticals in Q4 2024 and held it in 6 quarters.
Acorn Capital Advisors's X4 Pharmaceuticals position peaked at $5.36M in Q4 2024.
89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Acorn Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.